11 results on '"White, Michael T."'
Search Results
2. Heterogeneity in response to serological exposure markers of recent Plasmodium vivax infections in contrasting epidemiological contexts
- Author
-
Rosado, Jason, White, Michael T., Longley, Rhea J., Lacerda, Marcus, Monteiro, Wuelton, Brewster, Jessica, Sattabongkot, Jetsumon, Guzman-Guzman, Mitchel, Llanos-Cuentas, Alejandro, Vinetz, Joseph M., Gamboa, Dionicia, Mueller, Ivo, Malaria : parasites et hôtes - Malaria : parasites and hosts, Institut Pasteur [Paris], Santé publique : épidémiologie & sciences de l'information biomédicale (ED 393), Sorbonne Université (SU), The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, Instituto Leônidas e Maria Deane - Fiocruz Amazônia [Manaus, Brésil] (ILMD), Fundação Oswaldo Cruz (FIOCRUZ), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD), Mahidol University [Bangkok], Universidad Peruana Cayetano Heredia (UPCH), Yale University School of Medicine, This work was supported by National Health and Medical Research Council Australia grants 1092789, 1134989 and 1043345 to IM (https://www.nhmrc.gov.au/), the Global Health Innovative Technology Fund grant T2015-142 to IM (https://www.ghitfund.org/), National Institutes of Health-National Institute of Allergy and Infectious Diseases (NIH-NIAID) U19AI089681 to JMV (https://www.niaid.nih.gov). This work has been supported by FIND with funding from the Australian and British governments. The Brazilian team was partly funded by Fundação de Amparo à Pesquisa do Estado do Amazonas-FAPEAM (PAPAC 005/2019 and Pró-Estado). JR is supported by the Pasteur - Paris University (PPU) International PhD Program. RJL received the Page Betheras Award from WEHI to provide funding for technical support for this project during parental leave. RJL is supported by a NHMRC Early Career Investigator Fellowship (1173210). ML and WM are fellows of the Brazilian National Council for Scientific and Technological Development. MGG is supported by Training Grant 5D43TW007120 (https://www.fic.nih.gov)., Institut Pasteur [Paris] (IP), Fundação Oswaldo Cruz / Oswaldo Cruz Foundation (FIOCRUZ), and Yale School of Medicine [New Haven, Connecticut] (YSM)
- Subjects
Plasmodium ,Physiology ,RC955-962 ,serology ,immunogenicity ,Pathology and Laboratory Medicine ,Biochemistry ,Geographical locations ,Cohort Studies ,immunoglobulin G ,Medical Conditions ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Immune Physiology ,Arctic medicine. Tropical medicine ,Peru ,Medicine and Health Sciences ,Prevalence ,Longitudinal Studies ,Immune Response ,receiver operating characteristic ,Immune System Proteins ,seroprevalence ,Plasmodium vivax malaria ,Thailand ,Serology ,risk factor ,[SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology ,Antibody response ,pregnancy ,Public aspects of medicine ,RA1-1270 ,purl.org/pe-repo/ocde/ford#3.03.06 [https] ,Brazil ,Research Article ,Asia ,Immunology ,prevalence ,Plasmodium falciparum ,dispersity ,antibody titer ,Article ,Antibodies ,Parasite Groups ,parasitic diseases ,Parasitic Diseases ,Malaria, Vivax ,Humans ,follow up ,Serologic Tests ,human ,quality control ,Antigens ,Ascaris lumbricoides ,CD4+ T lymphocyte ,questionnaire ,Biology and Life Sciences ,Proteins ,antibody response ,South America ,Tropical Diseases ,vaccination ,discriminant analysis ,major clinical study ,enzyme linked immunosorbent assay ,Malaria ,sensitivity and specificity ,Immunoglobulin G ,Antibody Formation ,Parasitology ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,People and places ,Plasmodium vivax ,Apicomplexa ,Biomarkers - Abstract
Background Antibody responses as serological markers of Plasmodium vivax infection have been shown to correlate with exposure, but little is known about the other factors that affect antibody responses in naturally infected people from endemic settings. To address this question, we studied IgG responses to novel serological exposure markers (SEMs) of P. vivax in three settings with different transmission intensity. Methodology We validated a panel of 34 SEMs in a Peruvian cohort with up to three years’ longitudinal follow-up using a multiplex platform and compared results to data from cohorts in Thailand and Brazil. Linear regression models were used to characterize the association between antibody responses and age, the number of detected blood-stage infections during follow-up, and time since previous infection. Receiver Operating Characteristic (ROC) analysis was used to test the performance of SEMs to identify P. vivax infections in the previous 9 months. Principal findings Antibody titers were associated with age, the number of blood-stage infections, and time since previous P. vivax infection in all three study sites. The association between antibody titers and time since previous P. vivax infection was stronger in the low transmission settings of Thailand and Brazil compared to the higher transmission setting in Peru. Of the SEMs tested, antibody responses to RBP2b had the highest performance for classifying recent exposure in all sites, with area under the ROC curve (AUC) = 0.83 in Thailand, AUC = 0.79 in Brazil, and AUC = 0.68 in Peru. Conclusions In low transmission settings, P. vivax SEMs can accurately identify individuals with recent blood-stage infections. In higher transmission settings, the accuracy of this approach diminishes substantially. We recommend using P. vivax SEMs in low transmission settings pursuing malaria elimination, but they are likely to be less effective in high transmission settings focused on malaria control., Author summary Plasmodium vivax still poses a threat in many countries due to its ability to cause recurrent infections. Key to achieving the goal of malaria elimination is the ability to quickly detect and treat carriers of relapsing parasites. Failing to identify this transmission reservoir will hinder progress towards malaria elimination. Recently, novel serological markers of recent exposure to P. vivax (SEM) have been developed and validated in low transmission settings. It is still poorly understood what factors affect the antibody response to these markers when evaluated in contrasting endemic contexts. To determine the factors that influence the antibody response to SEM, we compared the antibody levels in three sites with different transmission intensity: Thailand (low), Brazil (moderate) and Peru (high). In this study, we found that transmission intensity plays a key role in the acquisition of the antibody repertoire to P. vivax. In highly endemic sites, it is likely that immunological memory resulting from a constant and sustained exposure will impact the performance of SEMs to detect individuals with recent exposure to P. vivax. In summary, SEMs that perform well in low transmission sites do not perform as well in high transmission regions.
- Published
- 2021
- Full Text
- View/download PDF
3. Antibodies to Plasmodium vivax reticulocyte binding protein 2b are associated with protection against P. vivax malaria in populations living in low malaria transmission regions of Brazil and Thailand.
- Author
-
He, Wen-Qiang, Karl, Stephan, White, Michael T., Nguitragool, Wang, Monteiro, Wuelton, Kuehn, Andrea, Gruszczyk, Jakub, França, Camila T., Sattabongkot, Jetsumon, Lacerda, Marcus V. G., Tham, Wai-Hong, and Mueller, Ivo
- Subjects
CARRIER proteins ,PLASMODIUM vivax ,CELLULAR recognition ,MALARIA ,ERYTHROCYTES - Abstract
Background: The Plasmodium vivax Reticulocyte Binding Protein (PvRBP) family is involved in red blood cell recognition and members of this family are potential targets for antibodies that may block P. vivax invasion. To date, the acquisition of immunity against PvRBPs in low malaria transmission settings and in a broad age group of exposed individuals has not been investigated. Methodology/Principal findings: Total IgG antibody levels to six members of the PvRBP family (PvRBP1a, PvRBP1b, PvRBP2a, PvRBP2b, a non-binding fragment of PvRBP2c (PvRBP2cNB) and PvRBP2-P2) were measured in samples collected from individuals living in two regions of low P. vivax endemicity in Brazil and Thailand. In both settings, levels of total IgG to PvRBP1a, PvRBP2b, PvRBP2cNB, and PvRBP2P-2 increased significantly with age (rho = 0.17–0.49; P<0.001). IgG responses to PvRBP1a, PvRBP2b and PvRBP2cNB were significantly higher in infected individuals by using Wilcoxon’s signed-rank test (P<0.001). Of the six PvRBPs examined, only antibodies to PvRBP2b were associated with protection against clinical malaria in both settings. Conclusion/Significance: Our results indicate that PvRBP2b warrants further preclinical development as a blood-stage vaccine candidate against P. vivax. Total IgG responses to PvRBPs were also shown to be promising immunological markers of exposure to P. vivax infection. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Antibody responses to merozoite antigens after natural Plasmodium falciparum infection: kinetics and longevity in absence of re-exposure.
- Author
-
Yman, Victor, White, Michael T., Asghar, Muhammad, Sundling, Christopher, Sondén, Klara, Draper, Simon J., Osier, Faith H. A., and Färnert, Anna
- Subjects
- *
MALARIA immunology , *ANTIBODY formation , *PLASMODIUM falciparum , *IMMUNE response , *MEROZOITES , *DYNAMICS - Abstract
Background: Antibodies against merozoite antigens are key components of malaria immunity. The naturally acquired antibody response to these antigens is generally considered short-lived; however, the underlying mechanisms remain unclear. Prospective studies of travellers with different levels of prior exposure, returning to malaria-free countries with Plasmodium infection, offer a unique opportunity to investigate the kinetics and composition of the antibody response after natural infection.Methods: Adults diagnosed with P. falciparum malaria in Stockholm, Sweden (20 likely malaria naïve and 41 with repeated previous exposure during residency in sub-Saharan Africa) were sampled at diagnosis and 10 days and 1, 3, 6, and 12 months after treatment. Total and subclass-specific IgG responses to P. falciparum merozoite antigens (AMA-1, MSP-119, MSP-2, MSP-3, and RH5) and tetanus toxoid were measured by multiplex bead-based immunoassays and ELISA. Mathematical modelling was used to estimate the exposure-dependent longevity of antibodies and antibody-secreting cells (ASCs).Results: A majority of individuals mounted detectable antibody responses towards P. falciparum merozoite antigens at diagnosis; however, the magnitude and breadth were greater in individuals with prior exposure. In both exposure groups, antibody levels increased rapidly for 2 weeks and decayed thereafter. Previously exposed individuals maintained two- to ninefold greater antibody levels throughout the 1-year follow-up. The half-lives of malaria-specific long-lived ASCs, responsible for maintaining circulating antibodies, ranged from 1.8 to 3.7 years for merozoite antigens and were considerably short compared to tetanus-specific ASCs. Primary infected individuals did acquire a long-lived component of the antibody response; however, the total proportion of long-lived ASCs generated in response to infection was estimated not to exceed 10%. In contrast, previously exposed individuals maintained substantially larger numbers of long-lived ASCs (10-56% of total ASCs).Conclusion: The short-lived nature of the naturally acquired antibody response, to all tested merozoite antigens, following primary malaria infection can be attributed to a combination of a poor acquisition and short half-life of long-lived ASCs. Greater longevity is acquired with repeated infections and can be explained by the maintenance of larger numbers of long-lived ASCs. These insights advance our understanding of naturally acquired malaria immunity and will guide strategies for further development of both vaccines and serological tools to monitor exposure. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
5. Naturally acquired antibody responses to more than 300 Plasmodium vivax proteins in three geographic regions.
- Author
-
Longley, Rhea J., White, Michael T., Takashima, Eizo, Morita, Masayuki, Kanoi, Bernard N., Li Wai Suen, Connie S. N., Betuela, Inoni, Kuehn, Andrea, Sripoorote, Piyarat, Franca, Camila T., Siba, Peter, Robinson, Leanne J., Lacerda, Marcus, Sattabongkot, Jetsumon, Tsuboi, Takafumi, and Mueller, Ivo
- Subjects
- *
PLASMODIUM vivax , *MALARIA treatment , *DIAGNOSIS - Abstract
Plasmodium vivax remains an important cause of malaria in South America and the Asia-Pacific. Naturally acquired antibody responses against multiple P. vivax proteins have been described in numerous countries, however, direct comparison of these responses has been difficult with different methodologies employed. We measured antibody responses against 307 P. vivax proteins at the time of P. vivax infection, and at 2–3 later time-points in three countries. We observed that seropositivity rates at the time of infection were highest in Thailand, followed by Brazil then PNG, reflecting the level of antigenic input. The majority of sero-reactive antigens in all sites induced short-lived antibody responses with estimated half-lives of less than 6 months, although there was a trend towards longer-lived responses in PNG children. Despite these differences, IgG seropositivity rates, magnitude and longevity were highly and significantly rank-correlated between the different regions, suggesting such features are reflective of the individual protein. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Asymptomatic Plasmodium vivax infections induce robust IgG responses to multiple blood-stage proteins in a low-transmission region of western Thailand.
- Author
-
Longley, Rhea J., França, Camila T., White, Michael T., Kumpitak, Chalermpon, Sa-angchai, Patiwat, Gruszczyk, Jakub, Hostetler, Jessica B., Yadava, Anjali, King, Christopher L., Fairhurst, Rick M., Rayner, Julian C., Wai-Hong Tham, Wang Nguitragool, Sattabongkot, Jetsumon, and Mueller, Ivo
- Subjects
PLASMODIUM vivax ,INFECTION ,IMMUNOGLOBULIN G ,HUMORAL immunity ,IMMUNE response - Abstract
Background: Thailand is aiming to eliminate malaria by the year 2024. Plasmodium vivax has now become the dominant species causing malaria within the country, and a high proportion of infections are asymptomatic. A better understanding of antibody dynamics to P. vivax antigens in a low-transmission setting, where acquired immune responses are poorly characterized, will be pivotal for developing new strategies for elimination, such as improved surveillance methods and vaccines. The objective of this study was to characterize total IgG antibody levels to 11 key P. vivax proteins in a village of western Thailand. Methods: Plasma samples from 546 volunteers enrolled in a cross-sectional survey conducted in 2012 in Kanchanaburi Province were utilized. Total IgG levels to 11 different proteins known or predicted to be involved in reticulocyte binding or invasion (ARP, GAMA, P41, P12, PVX_081550, and five members of the PvRBP family), as well as the leading pre-erythrocytic vaccine candidate (CSP) were measured using a multiplexed bead-based assay. Associations between IgG levels and infection status, age, and spatial location were explored. Results: Individuals from a low-transmission region of western Thailand reacted to all 11 P. vivax recombinant proteins. Significantly greater IgG levels were observed in the presence of a current P. vivax infection, despite all infected individuals being asymptomatic. IgG levels were also higher in adults (18 years and older) than in children. For most of the proteins, higher IgG levels were observed in individuals living closer to the Myanmar border and further away from local health services. Conclusions: Robust IgG responses were observed to most proteins and IgG levels correlated with surrogates of exposure, suggesting these antigens may serve as potential biomarkers of exposure, immunity, or both. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. An Antibody Screen of a Plasmodium vivax Antigen Library Identifies Novel Merozoite Proteins Associated with Clinical Protection.
- Author
-
França, Camila T., Hostetler, Jessica B., Sharma, Sumana, White, Michael T., Lin, Enmoore, Kiniboro, Benson, Waltmann, Andreea, Darcy, Andrew W., Li Wai Suen, Connie S. N., Siba, Peter, King, Christopher L., Rayner, Julian C., Fairhurst, Rick M., and Mueller, Ivo
- Subjects
PLASMODIUM vivax ,MALARIA vaccines ,BACTERIAL antibodies ,MEROZOITES ,SOCIOECONOMIC factors ,IMMUNE response - Abstract
Background: Elimination of Plasmodium vivax malaria would be greatly facilitated by the development of an effective vaccine. A comprehensive and systematic characterization of antibodies to P. vivax antigens in exposed populations is useful in guiding rational vaccine design. Methodology/Principal Findings: In this study, we investigated antibodies to a large library of P. vivax entire ectodomain merozoite proteins in 2 Asia-Pacific populations, analysing the relationship of antibody levels with markers of current and cumulative malaria exposure, and socioeconomic and clinical indicators. 29 antigenic targets of natural immunity were identified. Of these, 12 highly-immunogenic proteins were strongly associated with age and thus cumulative lifetime exposure in Solomon Islanders (P<0.001–0.027). A subset of 6 proteins, selected on the basis of immunogenicity and expression levels, were used to examine antibody levels in plasma samples from a population of young Papua New Guinean children with well-characterized individual differences in exposure. This analysis identified a strong association between reduced risk of clinical disease and antibody levels to P12, P41, and a novel hypothetical protein that has not previously been studied, PVX_081550 (IRR 0.46–0.74; P<0.001–0.041). Conclusion/Significance: These data emphasize the benefits of an unbiased screening approach in identifying novel vaccine candidate antigens. Functional studies are now required to establish whether PVX_081550 is a key component of the naturally-acquired protective immune response, a biomarker of immune status, or both. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. The design and statistical power of treatment re-infection studies of the association between pre-erythrocytic immunity and infection with Plasmodium falciparum.
- Author
-
White, Michael T., Griffin, Jamie T., and Ghani, Azra C.
- Subjects
- *
PLASMODIUM falciparum , *IMMUNE response , *MALARIA , *PARASITES , *SIMULATION methods & models - Abstract
Background: Understanding the role of pre-erythrocytic immune responses to Plasmodium falciparum parasites is crucial for understanding the epidemiology of malaria. However, published studies have reported inconsistent results on the association between markers of pre-erythrocytic immunity and protection from malaria. Methods: The design and statistical methods of studies of pre-erythrocytic immunity were reviewed, and factors affecting the likelihood of detecting statistically significant associations were assessed. Treatment re-infection studies were simulated to estimate the effects of study size, transmission intensity, and sampling frequency on the statistical power to detect an association between markers of pre-erythrocytic immunity and protection from infection. Results: Nine of nineteen studies reviewed reported statistically significant associations between markers of pre-erythrocytic immunity and protection from infection. Studies with large numbers of participants in high-transmission settings, followed longitudinally with active detection of infection and with immune responses analysed as continuous variables, were most likely to detect statistically significant associations. Simulation of treatment re-infection studies highlights that many studies are underpowered to detect statistically significant associations, providing an explanation for the finding that only some studies report significant associations between pre-erythrocytic immune responses and protection from infection. Conclusions: The findings of the review and model simulations are consistent with the hypothesis that pre-erythrocytic immune responses prevent P. falciparum infections, but that many studies are underpowered to consistently detect this effect. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
9. Synergism from combinations of infection-blocking malaria vaccines.
- Author
-
White, Michael T. and Smith, David L.
- Subjects
- *
MALARIA vaccines , *PLASMODIUM falciparum , *DRUG synergism , *IMMUNE response , *SPOROZOITES , *PARASITES - Abstract
Plasmodium falciparum infections present novel challenges for vaccine development, including parasite replication dynamics not previously encountered for viral pathogens, and enormous diversity in target antigens. These challenges are illustrated by using a mathematical model to describe the association between the proportion of pre-erythrocytic or blood-stage parasites eliminated by vaccine-induced immune responses and the proportion of infections prevented. It is hypothesized that due to the requirement for all sporozoites to be eliminated to prevent infection, combining infection-blocking vaccines that confer protection through different biological mechanisms could lead to synergistic combinations of efficacy. Vaccines targeting blood-stage parasites may also combine synergistically if they combine to reduce the parasite multiplication rate to below the threshold of 1. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. A comparative study of secretory immunoglobulin A and immunoglobulin G in host defense in an in vitro pneumonia model
- Author
-
Diebel, Lawrence N., Liberati, David M., White, Michael T., Diglio, Clement A., and Brown, William J.
- Subjects
- *
INFLAMMATION , *RESPIRATORY diseases , *INFECTION prevention , *MICROBIAL invasiveness , *RESPIRATORY infections , *CYTOLOGICAL research , *IMMUNOGLOBULIN A , *IMMUNE response - Abstract
Abstract: Background: An exaggerated inflammatory response to infections including nosocomial pneumonia may be detrimental to the host and contribute to morbidity and mortality. Both secretory immunoglobulin A (SIgA) and IgG contribute to the immune defense of respiratory surfaces. However, their relative ability to protect against invasive infections and the resultant host inflammatory response are unknown and were the basis for this study. Methods: Calu-3 cell (a respiratory epithelial cell line) monolayers were established in a Transwell system (Costar Corp., Cambridge, MA). Escherichia coli and either polyclonal SIgA or IgG were inoculated into the apical chamber and neutrophils (polymorphonuclear neutrophils) were added to the basal chamber. PMN cytotoxic potential was indexed by %CD11b expression, superoxide anion (O2−) production, and % elastase release. Bacterial translocation into the basal chamber was quantitated after log transformation. Calu-3 monolayer integrity was indexed by permeability to dextran fluorescein isothiocyanate. Results: The addition of E coli to Calu-3/polymorphonuclear cocultures led to increases in O2− generation, elastase release, and CD11b expression. These effects were diminished by the addition of SIgA but not IgG. A similar effect was noted with Calu-3 barrier function. Conclusions: SIgA may function to protect against microbial invasion of respiratory surfaces and protect against tissue injury from an exaggerated inflammatory response. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
11. Comprehensive analysis of antibody responses to Plasmodium falciparum erythrocyte membrane protein 1 domains.
- Author
-
Kanoi, Bernard N., Nagaoka, Hikaru, Morita, Masayuki, White, Michael T., Palacpac, Nirianne M.Q., Ntege, Edward H., Balikagala, Betty, Yeka, Adoke, Egwang, Thomas G., Horii, Toshihiro, Tsuboi, Takafumi, and Takashima, Eizo
- Subjects
- *
PLASMODIUM falciparum , *MALARIA immunology , *ERYTHROCYTE membranes , *MEMBRANE proteins , *IMMUNOGLOBULINS , *IMMUNITY , *MEROZOITES , *IMMUNE response - Abstract
Highlights • WGCFS coupled with AlphaScreen is ideal for high-throughput screening of protective antibodies. • DBL and CIDR domains are immunogenic in a Ugandan population. • A restricted set of specific domains are essential for eliciting protective immunity in malaria. • DC4 DBLβ3 is a target of protective antibodies in malaria. Abstract Acquired antibodies directed towards antigens expressed on the surface of merozoites and infected erythrocytes play an important role in protective immunity to Plasmodium falciparum malaria. P. falciparum erythrocyte membrane protein 1 (PfEMP1), the major parasite component of the infected erythrocyte surface, has been implicated in malaria pathology, parasite sequestration and host immune evasion. However, the extent to which unique PfEMP1 domains interact with host immune response remains largely unknown. In this study, we sought to comprehensively understand the naturally acquired antibody responses targeting different Duffy binding-like (DBL), and Cysteine-rich interdomain region (CIDR) domains in a Ugandan cohort. Consequently, we created a protein library consisting of full-length DBL (n = 163) and CIDR (n = 108) domains derived from 62-var genes based on 3D7 genome. The proteins were expressed by a wheat germ cell-free system; a system that yields plasmodial proteins that are comparatively soluble, intact, biologically active and immunoreactive to human sera. Our findings suggest that all PfEMP1 DBL and CIDR domains, regardless of PfEMP1 group, are targets of naturally acquired immunity. The breadth of the immune response expands with children's age. We concurrently identified 10 DBL and 8 CIDR domains whose antibody responses were associated with reduced risk to symptomatic malaria in the Ugandan children cohort. This study highlights that only a restricted set of specific domains are essential for eliciting naturally acquired protective immunity in malaria. In light of current data, tandem domains in PfEMP1s PF3D7_0700100 and PF3D7_0425800 (DC4) are recommended for extensive evaluation in larger population cohorts to further assess their potential as alternative targets for malaria vaccine development. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.